Background. Antibiotics are needed for perioperative intensive care after cardiovascular surgery, but use is sometimes excessive, requiring intervention.
Methods. We analyzed antibiotic use and patient characteristics after scheduled cardiovascular operations (including 76 coronary artery bypass grafting and 96 valve/arch replacements) in our hospital (726 beds and 8 intensive care unit [ICU] beds), excluding cases of infective vascular disorders (i.e., infectious endocarditis and mycotic aneurysm) and emergency operations. Observation periods were 8 months in 2013 (intervention period; IP) and the same period in 2012 ( pre-IP). For the intervention, an infectious disease [ID] fellow rounded on the ICU every day, and three times a week our ASP team (ID physician, clinical ID pharmacist, nurse, and microbiologist) discussed carbapenem and anti-methicillin-resistant Staphylococcus aureus [MRSA] drug administration for ward patients. Routine perioperative cefazolin was not included in the analysis.
Results. We analyzed 86 cases (540 patient-days [PDs] in the ICU and 3576 inpatient PDs) in the IP and 98 cases (619 ICU PDs and 4012 inpatient PDs) in the pre-IP. There were no statistically significant differences between the IP and pre-IP for male sex, age, BMI, operative bleeding, days hospitalized, ICU stay, and survival rate. MRSA and extended spectrum β-lactamase infections [ESBL] producing bacteria infections occurred in 9.3% vs 8.2% and 1.7% vs 3.1% of cases in the IP and pre-IP, respectively. Maximum sequential organ failure assessment [SOFA] scores during the ICU stay were higher in the IP (8.8 vs 7.6, P = 0.03, Mann-Whitney's test). Antibiotic use in the ICU did not differ significantly between periods (183.4 and 222.9 DOT/1,000 PDs), but was lower for the total hospital stay in IP vs pre-IP (142.9 vs 420.2 DOT/ 1,000 PDs, P < 0.001, chi-square test), especially for anti-MRSA drugs (17.7 vs 56.3 DOT/1,000 PDs, P < 0.001). The intervention shortened mean duration of anti-MRSA drug use to 5.2 from 9.8 days in the ICU and to 3.0 from 11.6 days in the ward. Total antibiotic expenditures in 8 months were 1.76 and 3.93 million JPY (IP and pre-IP, respectively).
Conclusion. The ASP team intervention decreased antibiotic use, optimizing anti-MRSA drug use, after cardiovascular surgeries without worsening patient prognosis in critical and ward care. 
